| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 84 | 2024 | 5458 | 5.440 |
Why?
|
| Lung Neoplasms | 94 | 2024 | 11638 | 4.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 83 | 2023 | 16327 | 1.900 |
Why?
|
| Quinazolines | 14 | 2022 | 934 | 1.370 |
Why?
|
| Niacinamide | 9 | 2013 | 423 | 1.160 |
Why?
|
| Carboplatin | 17 | 2019 | 844 | 1.040 |
Why?
|
| Benzenesulfonates | 4 | 2011 | 196 | 1.040 |
Why?
|
| Breast Neoplasms | 149 | 2017 | 16073 | 1.020 |
Why?
|
| Carcinoma, Squamous Cell | 21 | 2021 | 5495 | 1.000 |
Why?
|
| Head and Neck Neoplasms | 16 | 2023 | 4084 | 0.990 |
Why?
|
| Antineoplastic Agents | 73 | 2018 | 14558 | 0.950 |
Why?
|
| ErbB Receptors | 19 | 2022 | 2337 | 0.940 |
Why?
|
| Neoplasm Recurrence, Local | 29 | 2023 | 10282 | 0.870 |
Why?
|
| Antineoplastic Agents, Immunological | 10 | 2021 | 1331 | 0.840 |
Why?
|
| Angiogenesis Inhibitors | 8 | 2013 | 1269 | 0.830 |
Why?
|
| Paclitaxel | 17 | 2019 | 2061 | 0.830 |
Why?
|
| Indoles | 6 | 2013 | 1028 | 0.760 |
Why?
|
| Aged | 176 | 2024 | 73018 | 0.730 |
Why?
|
| Pyridines | 5 | 2020 | 1299 | 0.700 |
Why?
|
| Protein Kinase Inhibitors | 14 | 2022 | 4921 | 0.690 |
Why?
|
| Biomarkers, Tumor | 17 | 2021 | 10641 | 0.690 |
Why?
|
| Carcinoma, Large Cell | 4 | 2016 | 99 | 0.690 |
Why?
|
| Middle Aged | 197 | 2024 | 89661 | 0.670 |
Why?
|
| Humans | 299 | 2024 | 270969 | 0.640 |
Why?
|
| Antigens, Neoplasm | 3 | 2023 | 1561 | 0.630 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 5 | 2013 | 362 | 0.600 |
Why?
|
| Antibodies, Monoclonal, Humanized | 15 | 2023 | 3376 | 0.600 |
Why?
|
| Phenylurea Compounds | 6 | 2013 | 599 | 0.580 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2015 | 164 | 0.580 |
Why?
|
| Cetuximab | 14 | 2023 | 473 | 0.580 |
Why?
|
| Female | 225 | 2024 | 147624 | 0.560 |
Why?
|
| Erlotinib Hydrochloride | 11 | 2015 | 389 | 0.550 |
Why?
|
| Taxoids | 5 | 2017 | 992 | 0.550 |
Why?
|
| Neoplasm Metastasis | 77 | 2020 | 5250 | 0.540 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2022 | 1168 | 0.530 |
Why?
|
| Disease-Free Survival | 22 | 2017 | 10092 | 0.520 |
Why?
|
| Carcinoma, Adenoid Cystic | 2 | 2023 | 442 | 0.520 |
Why?
|
| Adult | 165 | 2023 | 80872 | 0.520 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2023 | 1907 | 0.500 |
Why?
|
| Neoplasm Staging | 31 | 2023 | 13883 | 0.500 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2015 | 45 | 0.500 |
Why?
|
| Platinum | 4 | 2023 | 141 | 0.480 |
Why?
|
| Immunotherapy | 15 | 2024 | 3518 | 0.480 |
Why?
|
| Male | 104 | 2024 | 127769 | 0.480 |
Why?
|
| Immunoconjugates | 3 | 2023 | 303 | 0.470 |
Why?
|
| Pemetrexed | 4 | 2023 | 102 | 0.460 |
Why?
|
| Survival Analysis | 18 | 2018 | 9311 | 0.460 |
Why?
|
| Antibodies, Monoclonal | 12 | 2023 | 4458 | 0.460 |
Why?
|
| Pyrimidinones | 2 | 2016 | 322 | 0.460 |
Why?
|
| B7-H1 Antigen | 9 | 2023 | 1061 | 0.440 |
Why?
|
| Molecular Targeted Therapy | 6 | 2013 | 2388 | 0.440 |
Why?
|
| Antineoplastic Agents, Phytogenic | 6 | 2015 | 882 | 0.440 |
Why?
|
| Pyridones | 2 | 2016 | 366 | 0.440 |
Why?
|
| Proto-Oncogene Proteins c-met | 3 | 2013 | 424 | 0.430 |
Why?
|
| Maximum Tolerated Dose | 11 | 2023 | 1316 | 0.420 |
Why?
|
| Pyrroles | 3 | 2013 | 591 | 0.420 |
Why?
|
| Aged, 80 and over | 40 | 2021 | 30845 | 0.420 |
Why?
|
| Oncogene Protein v-akt | 1 | 2012 | 104 | 0.420 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2015 | 498 | 0.410 |
Why?
|
| Doxorubicin | 57 | 1987 | 3060 | 0.410 |
Why?
|
| Treatment Outcome | 37 | 2023 | 34335 | 0.400 |
Why?
|
| Ipilimumab | 5 | 2023 | 754 | 0.400 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 5 | 2023 | 1379 | 0.390 |
Why?
|
| Receptors, Somatomedin | 1 | 2011 | 70 | 0.390 |
Why?
|
| Mitomycins | 12 | 1985 | 48 | 0.380 |
Why?
|
| Neoplasms | 22 | 2023 | 15797 | 0.380 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2023 | 1710 | 0.380 |
Why?
|
| Quinolines | 2 | 2012 | 398 | 0.380 |
Why?
|
| Neoplasm Proteins | 2 | 2023 | 3276 | 0.370 |
Why?
|
| T-Lymphocytes | 2 | 2022 | 3954 | 0.370 |
Why?
|
| Drug Administration Schedule | 27 | 2020 | 3512 | 0.360 |
Why?
|
| Prognosis | 52 | 2021 | 22348 | 0.360 |
Why?
|
| Anilides | 1 | 2012 | 290 | 0.350 |
Why?
|
| Mutation | 14 | 2023 | 15640 | 0.350 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2012 | 992 | 0.350 |
Why?
|
| Fluorouracil | 47 | 2019 | 1968 | 0.340 |
Why?
|
| BCG Vaccine | 28 | 1986 | 423 | 0.330 |
Why?
|
| Dose-Response Relationship, Drug | 19 | 2018 | 5021 | 0.320 |
Why?
|
| Adenocarcinoma | 11 | 2016 | 7877 | 0.310 |
Why?
|
| Tamoxifen | 14 | 1997 | 883 | 0.310 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2008 | 238 | 0.300 |
Why?
|
| Survival Rate | 19 | 2021 | 12475 | 0.300 |
Why?
|
| Thrombocytopenia | 9 | 2023 | 876 | 0.290 |
Why?
|
| Circulating Tumor DNA | 2 | 2021 | 257 | 0.290 |
Why?
|
| Cyclophosphamide | 49 | 1997 | 3150 | 0.290 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2012 | 1559 | 0.280 |
Why?
|
| GPI-Linked Proteins | 2 | 2020 | 231 | 0.270 |
Why?
|
| Follow-Up Studies | 27 | 2021 | 15255 | 0.270 |
Why?
|
| Pyridazines | 2 | 2019 | 314 | 0.260 |
Why?
|
| Oligonucleotides | 3 | 2011 | 232 | 0.260 |
Why?
|
| Hydroxamic Acids | 1 | 2007 | 447 | 0.250 |
Why?
|
| Bevacizumab | 6 | 2023 | 948 | 0.250 |
Why?
|
| Bone Neoplasms | 11 | 2012 | 2657 | 0.240 |
Why?
|
| Vinblastine | 12 | 2002 | 460 | 0.240 |
Why?
|
| Clinical Trials as Topic | 23 | 2020 | 3838 | 0.240 |
Why?
|
| Chemoradiotherapy | 7 | 2022 | 2006 | 0.240 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2018 | 6269 | 0.230 |
Why?
|
| Time Factors | 39 | 2018 | 13261 | 0.230 |
Why?
|
| Drug Resistance, Neoplasm | 10 | 2022 | 5298 | 0.230 |
Why?
|
| Maytansine | 2 | 2022 | 39 | 0.220 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2023 | 404 | 0.220 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2007 | 624 | 0.220 |
Why?
|
| Liver Neoplasms | 5 | 2018 | 4793 | 0.210 |
Why?
|
| Network Meta-Analysis | 1 | 2023 | 51 | 0.210 |
Why?
|
| Mucositis | 1 | 2023 | 150 | 0.210 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2011 | 1575 | 0.210 |
Why?
|
| Double-Blind Method | 5 | 2022 | 2649 | 0.210 |
Why?
|
| Bayes Theorem | 3 | 2023 | 1050 | 0.210 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 2 | 2013 | 109 | 0.200 |
Why?
|
| Combined Modality Therapy | 20 | 2023 | 9020 | 0.200 |
Why?
|
| Exons | 3 | 2022 | 1346 | 0.200 |
Why?
|
| Genes, erbB | 1 | 2021 | 27 | 0.200 |
Why?
|
| Methotrexate | 23 | 2017 | 1023 | 0.190 |
Why?
|
| Lymphopenia | 1 | 2023 | 209 | 0.190 |
Why?
|
| Administration, Oral | 7 | 2015 | 1583 | 0.190 |
Why?
|
| Arthritis | 1 | 2022 | 144 | 0.190 |
Why?
|
| Tissue Distribution | 3 | 2012 | 907 | 0.190 |
Why?
|
| Piperazines | 3 | 2019 | 2143 | 0.180 |
Why?
|
| Lymphocyte Depletion | 1 | 2022 | 295 | 0.180 |
Why?
|
| Bone Marrow | 12 | 1997 | 2393 | 0.180 |
Why?
|
| Bone Marrow Transplantation | 4 | 1997 | 1615 | 0.180 |
Why?
|
| Genetic Engineering | 1 | 2022 | 289 | 0.180 |
Why?
|
| Drug Therapy, Combination | 49 | 1992 | 2342 | 0.170 |
Why?
|
| Skin Neoplasms | 4 | 2021 | 4744 | 0.170 |
Why?
|
| Radiology, Interventional | 1 | 2020 | 141 | 0.170 |
Why?
|
| Aminoglutethimide | 3 | 1984 | 13 | 0.170 |
Why?
|
| Hormones | 5 | 1985 | 276 | 0.160 |
Why?
|
| Carcinoma | 11 | 2007 | 2602 | 0.160 |
Why?
|
| Consolidation Chemotherapy | 1 | 2019 | 156 | 0.160 |
Why?
|
| Receptor, ErbB-3 | 2 | 2017 | 126 | 0.160 |
Why?
|
| Drug Evaluation | 29 | 1987 | 427 | 0.160 |
Why?
|
| Receptors, Estrogen | 10 | 2012 | 2131 | 0.150 |
Why?
|
| Signal Transduction | 5 | 2015 | 12145 | 0.150 |
Why?
|
| Receptor, ErbB-2 | 5 | 2021 | 2629 | 0.150 |
Why?
|
| Disease Progression | 8 | 2020 | 6881 | 0.150 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2014 | 2564 | 0.140 |
Why?
|
| Neoplasms, Hormone-Dependent | 4 | 1985 | 347 | 0.140 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2010 | 760 | 0.140 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 3 | 2011 | 74 | 0.140 |
Why?
|
| Neoadjuvant Therapy | 3 | 2024 | 5156 | 0.130 |
Why?
|
| HLA Antigens | 1 | 2019 | 557 | 0.130 |
Why?
|
| Nausea | 8 | 2009 | 537 | 0.130 |
Why?
|
| Papillomaviridae | 1 | 2019 | 626 | 0.130 |
Why?
|
| Proportional Hazards Models | 6 | 2018 | 5094 | 0.130 |
Why?
|
| Drug Delivery Systems | 2 | 2011 | 683 | 0.130 |
Why?
|
| Image-Guided Biopsy | 2 | 2020 | 334 | 0.130 |
Why?
|
| ras Proteins | 3 | 2014 | 784 | 0.130 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2017 | 679 | 0.120 |
Why?
|
| Gene Frequency | 2 | 2021 | 1125 | 0.120 |
Why?
|
| Medroxyprogesterone | 2 | 1985 | 14 | 0.120 |
Why?
|
| Sesquiterpenes | 3 | 2004 | 71 | 0.120 |
Why?
|
| Megestrol | 3 | 1983 | 15 | 0.120 |
Why?
|
| src-Family Kinases | 2 | 2014 | 480 | 0.120 |
Why?
|
| Cisplatin | 8 | 2019 | 2465 | 0.120 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2014 | 525 | 0.110 |
Why?
|
| Radiosurgery | 1 | 2023 | 1376 | 0.110 |
Why?
|
| Patient Selection | 3 | 2012 | 2111 | 0.110 |
Why?
|
| Hematopoietic Stem Cells | 3 | 1997 | 1296 | 0.110 |
Why?
|
| Eyelid Neoplasms | 2 | 2008 | 194 | 0.110 |
Why?
|
| Camptothecin | 3 | 2010 | 536 | 0.110 |
Why?
|
| Retrospective Studies | 13 | 2023 | 39724 | 0.110 |
Why?
|
| Survival | 1 | 2013 | 176 | 0.110 |
Why?
|
| Dasatinib | 2 | 2014 | 879 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2018 | 2717 | 0.110 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2011 | 189 | 0.110 |
Why?
|
| Carcinoembryonic Antigen | 3 | 1983 | 229 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2021 | 1369 | 0.110 |
Why?
|
| Anorexia | 2 | 2017 | 147 | 0.100 |
Why?
|
| Gene Dosage | 2 | 2012 | 834 | 0.100 |
Why?
|
| Translocation, Genetic | 1 | 2018 | 1269 | 0.100 |
Why?
|
| Remission Induction | 3 | 2015 | 3622 | 0.100 |
Why?
|
| Radiation Pneumonitis | 3 | 2018 | 308 | 0.100 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 1930 | 0.100 |
Why?
|
| Immunoglobulin G | 2 | 2015 | 1065 | 0.100 |
Why?
|
| Tetrahydronaphthalenes | 2 | 2012 | 117 | 0.100 |
Why?
|
| Aminoacridines | 5 | 1986 | 23 | 0.100 |
Why?
|
| Lymphatic Metastasis | 9 | 2012 | 4940 | 0.100 |
Why?
|
| Salvage Therapy | 3 | 2015 | 2099 | 0.100 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2011 | 86 | 0.100 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2023 | 1071 | 0.100 |
Why?
|
| Neovascularization, Pathologic | 2 | 2008 | 1583 | 0.090 |
Why?
|
| Biological Availability | 2 | 2011 | 223 | 0.090 |
Why?
|
| Catalytic Domain | 1 | 2012 | 308 | 0.090 |
Why?
|
| Mitoxantrone | 8 | 1995 | 220 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2012 | 275 | 0.090 |
Why?
|
| Leukopenia | 6 | 1985 | 150 | 0.090 |
Why?
|
| Carcinoma, Small Cell | 2 | 2003 | 416 | 0.090 |
Why?
|
| Radiography, Thoracic | 1 | 2013 | 461 | 0.090 |
Why?
|
| Piperidines | 2 | 2013 | 1066 | 0.090 |
Why?
|
| Tumor Stem Cell Assay | 3 | 1985 | 232 | 0.090 |
Why?
|
| Brain Neoplasms | 5 | 2023 | 5019 | 0.090 |
Why?
|
| Papillomavirus Infections | 1 | 2019 | 1009 | 0.090 |
Why?
|
| Trigeminal Nerve Diseases | 1 | 2009 | 15 | 0.090 |
Why?
|
| Tongue Neoplasms | 1 | 2011 | 252 | 0.080 |
Why?
|
| Thyroid Neoplasms | 1 | 2020 | 1900 | 0.080 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2009 | 48 | 0.080 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2011 | 353 | 0.080 |
Why?
|
| Etoposide | 5 | 2010 | 888 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 2 | 2015 | 4064 | 0.080 |
Why?
|
| Genes, ras | 1 | 2012 | 670 | 0.080 |
Why?
|
| Facial Neoplasms | 1 | 2009 | 80 | 0.080 |
Why?
|
| Colony-Forming Units Assay | 3 | 1985 | 246 | 0.080 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2012 | 671 | 0.080 |
Why?
|
| Meningeal Neoplasms | 5 | 1982 | 463 | 0.080 |
Why?
|
| Fatigue | 2 | 2017 | 1267 | 0.080 |
Why?
|
| Bronchial Neoplasms | 2 | 1978 | 79 | 0.080 |
Why?
|
| Capsules | 1 | 2007 | 54 | 0.080 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2009 | 232 | 0.080 |
Why?
|
| Salivary Ducts | 1 | 2007 | 56 | 0.070 |
Why?
|
| Adenocarcinoma, Sebaceous | 1 | 2008 | 66 | 0.070 |
Why?
|
| Menopause | 10 | 1985 | 165 | 0.070 |
Why?
|
| Castration | 8 | 1983 | 121 | 0.070 |
Why?
|
| Proton Therapy | 1 | 2018 | 1613 | 0.070 |
Why?
|
| Environment, Controlled | 1 | 1987 | 21 | 0.070 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2008 | 100 | 0.070 |
Why?
|
| Hypertriglyceridemia | 1 | 2008 | 110 | 0.070 |
Why?
|
| Parotid Neoplasms | 1 | 2008 | 150 | 0.070 |
Why?
|
| Quality of Life | 3 | 2017 | 4737 | 0.070 |
Why?
|
| Dyspnea | 2 | 2022 | 422 | 0.070 |
Why?
|
| Infusions, Intravenous | 7 | 2005 | 1414 | 0.070 |
Why?
|
| Precision Medicine | 2 | 2013 | 1213 | 0.070 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2018 | 2129 | 0.070 |
Why?
|
| Drug Therapy | 2 | 2007 | 204 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2011 | 687 | 0.070 |
Why?
|
| Dendritic Cells | 1 | 2013 | 1117 | 0.070 |
Why?
|
| Melanoma | 2 | 2023 | 5393 | 0.070 |
Why?
|
| Tumor Microenvironment | 3 | 2023 | 3002 | 0.070 |
Why?
|
| Thiazoles | 1 | 2010 | 725 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2019 | 9466 | 0.070 |
Why?
|
| Pyrimidines | 3 | 2020 | 3636 | 0.070 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2006 | 69 | 0.070 |
Why?
|
| Pleural Effusion | 5 | 1985 | 215 | 0.070 |
Why?
|
| Diarrhea | 1 | 2009 | 697 | 0.060 |
Why?
|
| Hypercalcemia | 3 | 1981 | 143 | 0.060 |
Why?
|
| Vinca Alkaloids | 1 | 1985 | 9 | 0.060 |
Why?
|
| Mitolactol | 2 | 1984 | 5 | 0.060 |
Why?
|
| Forecasting | 1 | 2008 | 705 | 0.060 |
Why?
|
| Molecular Epidemiology | 1 | 2006 | 236 | 0.060 |
Why?
|
| Fever | 4 | 1984 | 512 | 0.060 |
Why?
|
| Neoplasm Transplantation | 1 | 2008 | 1533 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2008 | 7105 | 0.060 |
Why?
|
| Stomach Neoplasms | 1 | 2017 | 2349 | 0.060 |
Why?
|
| Immunohistochemistry | 5 | 2018 | 7711 | 0.060 |
Why?
|
| Anthraquinones | 4 | 1985 | 27 | 0.060 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2022 | 562 | 0.060 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2018 | 2434 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2007 | 2270 | 0.060 |
Why?
|
| Bone Marrow Diseases | 2 | 1984 | 184 | 0.060 |
Why?
|
| Amifostine | 1 | 2004 | 97 | 0.060 |
Why?
|
| Heart Failure | 9 | 1985 | 2674 | 0.060 |
Why?
|
| Esophageal Neoplasms | 1 | 2017 | 3258 | 0.060 |
Why?
|
| Radiation-Protective Agents | 1 | 2004 | 129 | 0.060 |
Why?
|
| Remission, Spontaneous | 13 | 1980 | 122 | 0.060 |
Why?
|
| Estradiol | 2 | 1985 | 769 | 0.060 |
Why?
|
| Paralysis | 1 | 1983 | 51 | 0.060 |
Why?
|
| Peptichemio | 5 | 1984 | 12 | 0.060 |
Why?
|
| Tumor Burden | 3 | 2019 | 2020 | 0.060 |
Why?
|
| Vincristine | 8 | 1985 | 1533 | 0.060 |
Why?
|
| DEAE-Dextran | 1 | 1983 | 3 | 0.060 |
Why?
|
| Mastectomy | 9 | 1986 | 1569 | 0.050 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2023 | 107 | 0.050 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 1986 | 558 | 0.050 |
Why?
|
| Skull Neoplasms | 1 | 1983 | 68 | 0.050 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2013 | 1307 | 0.050 |
Why?
|
| Glaucarubin | 1 | 1982 | 1 | 0.050 |
Why?
|
| Injections, Subcutaneous | 3 | 2003 | 345 | 0.050 |
Why?
|
| Quassins | 1 | 1982 | 3 | 0.050 |
Why?
|
| Dextrans | 1 | 1983 | 92 | 0.050 |
Why?
|
| Lymphocytes | 3 | 2020 | 1220 | 0.050 |
Why?
|
| HLA-A Antigens | 1 | 2023 | 104 | 0.050 |
Why?
|
| Cranial Nerve Diseases | 1 | 1983 | 73 | 0.050 |
Why?
|
| Phenanthrenes | 1 | 1982 | 42 | 0.050 |
Why?
|
| Thinness | 1 | 2023 | 83 | 0.050 |
Why?
|
| Age Factors | 5 | 2019 | 5498 | 0.050 |
Why?
|
| Induction Chemotherapy | 2 | 2019 | 672 | 0.050 |
Why?
|
| Valproic Acid | 1 | 2023 | 268 | 0.050 |
Why?
|
| Daunorubicin | 2 | 1984 | 304 | 0.050 |
Why?
|
| Arthrogryposis | 1 | 2022 | 34 | 0.050 |
Why?
|
| Biological Therapy | 1 | 2002 | 55 | 0.050 |
Why?
|
| Genomics | 2 | 2024 | 2845 | 0.050 |
Why?
|
| Prospective Studies | 8 | 2023 | 13336 | 0.050 |
Why?
|
| Recurrence | 5 | 2023 | 4889 | 0.050 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1984 | 395 | 0.050 |
Why?
|
| Area Under Curve | 2 | 2015 | 718 | 0.050 |
Why?
|
| Neutropenia | 4 | 2010 | 987 | 0.050 |
Why?
|
| Diazoxide | 1 | 1980 | 7 | 0.050 |
Why?
|
| Vomiting | 7 | 1984 | 361 | 0.050 |
Why?
|
| Radiotherapy Dosage | 5 | 2015 | 3984 | 0.050 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2023 | 261 | 0.050 |
Why?
|
| Hematoma, Subdural | 1 | 1980 | 28 | 0.050 |
Why?
|
| Random Allocation | 7 | 1987 | 714 | 0.050 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2003 | 285 | 0.050 |
Why?
|
| Ifosfamide | 3 | 2011 | 354 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2018 | 2258 | 0.050 |
Why?
|
| Radiotherapy, High-Energy | 2 | 1981 | 300 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2017 | 479 | 0.050 |
Why?
|
| Deoxycytidine | 2 | 2005 | 1375 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2023 | 449 | 0.050 |
Why?
|
| Ischemia | 1 | 2023 | 402 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2013 | 9065 | 0.050 |
Why?
|
| Immune Complex Diseases | 1 | 1980 | 12 | 0.040 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2002 | 167 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 1425 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 4 | 2002 | 730 | 0.040 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2023 | 386 | 0.040 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 1980 | 122 | 0.040 |
Why?
|
| Adolescent | 7 | 2023 | 32464 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2012 | 7333 | 0.040 |
Why?
|
| Glomerulonephritis | 1 | 1980 | 113 | 0.040 |
Why?
|
| Infusions, Parenteral | 8 | 1992 | 191 | 0.040 |
Why?
|
| Leucovorin | 4 | 1984 | 340 | 0.040 |
Why?
|
| Liver Diseases | 2 | 1983 | 597 | 0.040 |
Why?
|
| Heart Diseases | 1 | 1985 | 759 | 0.040 |
Why?
|
| Amenorrhea | 1 | 1978 | 34 | 0.040 |
Why?
|
| Pulmonary Fibrosis | 1 | 1980 | 175 | 0.040 |
Why?
|
| Nails | 1 | 1978 | 36 | 0.040 |
Why?
|
| Cytarabine | 1 | 1985 | 1994 | 0.040 |
Why?
|
| Pigmentation Disorders | 1 | 1978 | 39 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2015 | 2371 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2019 | 745 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2023 | 1866 | 0.040 |
Why?
|
| Interleukin-2 | 2 | 1992 | 851 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 1980 | 475 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2020 | 375 | 0.040 |
Why?
|
| Pituitary Gland | 1 | 1978 | 149 | 0.040 |
Why?
|
| Alopecia | 5 | 1984 | 126 | 0.040 |
Why?
|
| Social Participation | 1 | 2017 | 23 | 0.040 |
Why?
|
| Receptors, Progesterone | 3 | 2012 | 1413 | 0.040 |
Why?
|
| Sensation Disorders | 1 | 2017 | 38 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2022 | 1477 | 0.040 |
Why?
|
| Thiotepa | 2 | 1995 | 124 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 1995 | 6814 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2020 | 703 | 0.040 |
Why?
|
| Antigens, CD19 | 1 | 2020 | 590 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 4462 | 0.040 |
Why?
|
| Drug Resistance | 5 | 1985 | 598 | 0.030 |
Why?
|
| Hematologic Diseases | 2 | 2010 | 246 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 1982 | 1916 | 0.030 |
Why?
|
| Prednisone | 4 | 1984 | 998 | 0.030 |
Why?
|
| Lymph Nodes | 3 | 2019 | 3037 | 0.030 |
Why?
|
| Leukocyte Count | 5 | 1987 | 707 | 0.030 |
Why?
|
| Anthracenes | 4 | 1986 | 48 | 0.030 |
Why?
|
| Tissue Preservation | 1 | 1995 | 28 | 0.030 |
Why?
|
| Cell Count | 1 | 1997 | 508 | 0.030 |
Why?
|
| Animals | 7 | 2018 | 61175 | 0.030 |
Why?
|
| Carmustine | 1 | 1995 | 215 | 0.030 |
Why?
|
| Anesthesia, Local | 1 | 1995 | 65 | 0.030 |
Why?
|
| Young Adult | 4 | 2018 | 22268 | 0.030 |
Why?
|
| Mitomycin | 3 | 1985 | 207 | 0.030 |
Why?
|
| Melphalan | 3 | 1982 | 839 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 1980 | 1699 | 0.030 |
Why?
|
| Blood Cell Count | 7 | 1983 | 226 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2023 | 2281 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 829 | 0.030 |
Why?
|
| Cell Line, Tumor | 3 | 2018 | 14928 | 0.030 |
Why?
|
| Lectins | 2 | 1974 | 153 | 0.030 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 1985 | 55 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 1663 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2003 | 3968 | 0.030 |
Why?
|
| Ovary | 1 | 1978 | 686 | 0.030 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1979 | 694 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2019 | 795 | 0.030 |
Why?
|
| Cyclohexanes | 2 | 2004 | 39 | 0.030 |
Why?
|
| Enterotoxins | 1 | 1974 | 112 | 0.030 |
Why?
|
| Risk | 5 | 1987 | 1942 | 0.030 |
Why?
|
| Lipocalins | 1 | 2013 | 54 | 0.030 |
Why?
|
| Interleukin-9 | 1 | 2013 | 37 | 0.030 |
Why?
|
| Transcription Factors | 2 | 2023 | 5360 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 1806 | 0.030 |
Why?
|
| Megestrol Acetate | 2 | 1983 | 31 | 0.030 |
Why?
|
| Acute-Phase Proteins | 1 | 2013 | 81 | 0.030 |
Why?
|
| Lipocalin-2 | 1 | 2013 | 69 | 0.030 |
Why?
|
| Genes, erbB-1 | 1 | 2013 | 102 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2012 | 4887 | 0.030 |
Why?
|
| Everolimus | 1 | 2015 | 425 | 0.030 |
Why?
|
| Agranulocytosis | 5 | 2004 | 79 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2015 | 319 | 0.030 |
Why?
|
| Sleep Stages | 2 | 1982 | 81 | 0.030 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2013 | 209 | 0.030 |
Why?
|
| Outpatients | 1 | 1995 | 475 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 2348 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2013 | 473 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2011 | 85 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2023 | 3362 | 0.020 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2015 | 335 | 0.020 |
Why?
|
| Amsacrine | 4 | 1986 | 62 | 0.020 |
Why?
|
| Biomarkers | 1 | 2023 | 5161 | 0.020 |
Why?
|
| Half-Life | 2 | 2010 | 265 | 0.020 |
Why?
|
| Hypotension | 2 | 1985 | 218 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2011 | 80 | 0.020 |
Why?
|
| Glossectomy | 1 | 2011 | 44 | 0.020 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1991 | 50 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2020 | 1532 | 0.020 |
Why?
|
| Aspartic Acid | 1 | 2012 | 127 | 0.020 |
Why?
|
| Sirolimus | 1 | 2016 | 832 | 0.020 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 842 | 0.020 |
Why?
|
| Valine | 1 | 2012 | 183 | 0.020 |
Why?
|
| Lentivirus | 1 | 2012 | 172 | 0.020 |
Why?
|
| Stomatitis | 2 | 1984 | 187 | 0.020 |
Why?
|
| Pain Measurement | 1 | 1995 | 1004 | 0.020 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2011 | 155 | 0.020 |
Why?
|
| Levamisole | 3 | 1979 | 12 | 0.020 |
Why?
|
| Cell Line | 3 | 1985 | 5122 | 0.020 |
Why?
|
| Asparaginase | 3 | 1981 | 186 | 0.020 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2011 | 136 | 0.020 |
Why?
|
| Cysteine | 1 | 2012 | 214 | 0.020 |
Why?
|
| Genotype | 1 | 2019 | 4015 | 0.020 |
Why?
|
| Nitrosourea Compounds | 2 | 1982 | 12 | 0.020 |
Why?
|
| Nervous System Neoplasms | 2 | 1980 | 36 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2012 | 395 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 1995 | 1977 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 590 | 0.020 |
Why?
|
| Neck Dissection | 1 | 2011 | 296 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 613 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2013 | 745 | 0.020 |
Why?
|
| Ovarian Neoplasms | 2 | 1984 | 4720 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2012 | 901 | 0.020 |
Why?
|
| Gene Expression Profiling | 2 | 2012 | 5228 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2010 | 181 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 5015 | 0.020 |
Why?
|
| Obesity | 1 | 2023 | 2983 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 1081 | 0.020 |
Why?
|
| Diagnostic Errors | 2 | 2008 | 524 | 0.020 |
Why?
|
| Glycine | 1 | 2012 | 306 | 0.020 |
Why?
|
| Texas | 4 | 2010 | 6489 | 0.020 |
Why?
|
| Radiotherapy, Conformal | 1 | 2015 | 908 | 0.020 |
Why?
|
| Lung | 1 | 2020 | 3234 | 0.020 |
Why?
|
| Clone Cells | 3 | 1985 | 559 | 0.020 |
Why?
|
| Moloney murine leukemia virus | 1 | 1969 | 24 | 0.020 |
Why?
|
| Skin Diseases | 2 | 1982 | 359 | 0.020 |
Why?
|
| Cheek | 1 | 2009 | 72 | 0.020 |
Why?
|
| Bacterial Infections | 2 | 1984 | 486 | 0.020 |
Why?
|
| Rats | 1 | 2018 | 6233 | 0.020 |
Why?
|
| Sarcoma, Experimental | 1 | 1969 | 68 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2013 | 1398 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 448 | 0.020 |
Why?
|
| Pain | 1 | 2017 | 1689 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 1348 | 0.020 |
Why?
|
| Proteome | 1 | 2012 | 577 | 0.020 |
Why?
|
| Mice | 5 | 2018 | 35455 | 0.020 |
Why?
|
| Androgens | 2 | 1983 | 519 | 0.020 |
Why?
|
| Chalazion | 1 | 2008 | 2 | 0.020 |
Why?
|
| Prolactin | 2 | 1978 | 159 | 0.020 |
Why?
|
| Vindesine | 2 | 1985 | 11 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 3487 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 1983 | 622 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 1992 | 905 | 0.020 |
Why?
|
| Estrogens | 2 | 1983 | 758 | 0.020 |
Why?
|
| Triazines | 2 | 1979 | 118 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2011 | 1690 | 0.020 |
Why?
|
| Co-Repressor Proteins | 1 | 2007 | 120 | 0.020 |
Why?
|
| Cells, Cultured | 3 | 1985 | 5677 | 0.020 |
Why?
|
| Premedication | 1 | 1987 | 133 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2010 | 1800 | 0.020 |
Why?
|
| Estrogen Receptor beta | 1 | 2007 | 159 | 0.020 |
Why?
|
| Soft Tissue Neoplasms | 3 | 1984 | 912 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2012 | 1718 | 0.020 |
Why?
|
| Palliative Care | 3 | 1982 | 2149 | 0.020 |
Why?
|
| Drug Eruptions | 2 | 2005 | 268 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 1985 | 509 | 0.020 |
Why?
|
| Risk Factors | 2 | 2018 | 18036 | 0.020 |
Why?
|
| Benzamides | 1 | 2011 | 1876 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2013 | 7765 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 3 | 1981 | 414 | 0.020 |
Why?
|
| DNA | 1 | 1974 | 2733 | 0.020 |
Why?
|
| Pyrrolidines | 1 | 1986 | 114 | 0.020 |
Why?
|
| Glutamates | 1 | 2005 | 131 | 0.020 |
Why?
|
| Rhabdomyosarcoma | 1 | 1969 | 348 | 0.020 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2005 | 122 | 0.020 |
Why?
|
| Guanine | 1 | 2005 | 152 | 0.020 |
Why?
|
| Injections, Intraventricular | 2 | 1982 | 115 | 0.020 |
Why?
|
| Proteomics | 1 | 2012 | 1431 | 0.020 |
Why?
|
| Estrogen Antagonists | 1 | 1986 | 185 | 0.020 |
Why?
|
| Germanium | 1 | 1984 | 7 | 0.020 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2008 | 281 | 0.020 |
Why?
|
| Neoplasm Regression, Spontaneous | 2 | 1978 | 35 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 7456 | 0.020 |
Why?
|
| Spiro Compounds | 1 | 1984 | 59 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 2081 | 0.010 |
Why?
|
| Carubicin | 1 | 1984 | 2 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 2005 | 324 | 0.010 |
Why?
|
| Immunity, Cellular | 2 | 1980 | 429 | 0.010 |
Why?
|
| Amphotericin B | 2 | 1978 | 294 | 0.010 |
Why?
|
| Intercalating Agents | 1 | 1983 | 30 | 0.010 |
Why?
|
| Anemia | 1 | 2010 | 740 | 0.010 |
Why?
|
| United States | 3 | 2015 | 16325 | 0.010 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 1985 | 121 | 0.010 |
Why?
|
| Eye Enucleation | 1 | 2003 | 87 | 0.010 |
Why?
|
| Cell Division | 2 | 1985 | 2555 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2014 | 16882 | 0.010 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2003 | 179 | 0.010 |
Why?
|
| Propionibacterium acnes | 2 | 1980 | 25 | 0.010 |
Why?
|
| Organometallic Compounds | 1 | 1984 | 195 | 0.010 |
Why?
|
| Azirines | 1 | 1983 | 5 | 0.010 |
Why?
|
| Aziridines | 1 | 1983 | 18 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2005 | 568 | 0.010 |
Why?
|
| Blood Chemical Analysis | 1 | 1983 | 115 | 0.010 |
Why?
|
| Axilla | 2 | 1983 | 922 | 0.010 |
Why?
|
| Specimen Handling | 1 | 1985 | 302 | 0.010 |
Why?
|
| Diethylstilbestrol | 1 | 1983 | 89 | 0.010 |
Why?
|
| Tegafur | 2 | 1979 | 50 | 0.010 |
Why?
|
| Dizziness | 1 | 1982 | 47 | 0.010 |
Why?
|
| Benzoquinones | 1 | 1983 | 112 | 0.010 |
Why?
|
| Interphase | 1 | 1982 | 145 | 0.010 |
Why?
|
| Skin Tests | 2 | 1981 | 98 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2004 | 760 | 0.010 |
Why?
|
| Orbit | 1 | 2003 | 212 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 6181 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2007 | 2110 | 0.010 |
Why?
|
| Thyrotropin-Releasing Hormone | 2 | 1978 | 16 | 0.010 |
Why?
|
| Cardiomyopathies | 2 | 1985 | 626 | 0.010 |
Why?
|
| Injections, Spinal | 1 | 1982 | 267 | 0.010 |
Why?
|
| Receptors, Androgen | 1 | 2007 | 892 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 1983 | 4867 | 0.010 |
Why?
|
| Mitoguazone | 1 | 1981 | 9 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 2192 | 0.010 |
Why?
|
| Cobalt Radioisotopes | 1 | 1981 | 45 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1983 | 654 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2011 | 6034 | 0.010 |
Why?
|
| Breast Diseases | 2 | 1980 | 205 | 0.010 |
Why?
|
| Guanidines | 1 | 1981 | 61 | 0.010 |
Why?
|
| Cytokines | 1 | 2010 | 2870 | 0.010 |
Why?
|
| Subdural Space | 1 | 1980 | 8 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2007 | 1599 | 0.010 |
Why?
|
| Aneuploidy | 1 | 1982 | 373 | 0.010 |
Why?
|
| Hernia | 1 | 1980 | 46 | 0.010 |
Why?
|
| Edema | 1 | 1982 | 269 | 0.010 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 1980 | 37 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1983 | 1547 | 0.010 |
Why?
|
| Altretamine | 1 | 1979 | 4 | 0.010 |
Why?
|
| Radioisotope Teletherapy | 1 | 1979 | 12 | 0.010 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 1980 | 73 | 0.010 |
Why?
|
| Heart | 3 | 1986 | 1261 | 0.010 |
Why?
|
| Electrons | 1 | 1981 | 179 | 0.010 |
Why?
|
| Diabetes Insipidus | 1 | 1979 | 26 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 1985 | 602 | 0.010 |
Why?
|
| Skin Ulcer | 1 | 1980 | 78 | 0.010 |
Why?
|
| Trichothecenes | 1 | 1979 | 6 | 0.010 |
Why?
|
| Bacterial Vaccines | 1 | 1980 | 104 | 0.010 |
Why?
|
| Alleles | 1 | 2006 | 2398 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1983 | 2304 | 0.010 |
Why?
|
| Urogenital Neoplasms | 1 | 1980 | 112 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1980 | 618 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1979 | 116 | 0.010 |
Why?
|
| Interferons | 1 | 1980 | 300 | 0.010 |
Why?
|
| Prevalence | 1 | 2007 | 3399 | 0.010 |
Why?
|
| Child | 2 | 2014 | 30357 | 0.010 |
Why?
|
| Thyrotropin | 1 | 1978 | 118 | 0.010 |
Why?
|
| Biopsy | 3 | 1982 | 3502 | 0.010 |
Why?
|
| Lomustine | 1 | 1978 | 41 | 0.010 |
Why?
|
| Luteinizing Hormone | 1 | 1978 | 173 | 0.010 |
Why?
|
| Sarcoma | 3 | 1978 | 1831 | 0.010 |
Why?
|
| Heart Neoplasms | 1 | 1980 | 215 | 0.010 |
Why?
|
| Paraplegia | 1 | 1978 | 98 | 0.010 |
Why?
|
| Follicle Stimulating Hormone | 1 | 1978 | 249 | 0.010 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 1978 | 168 | 0.010 |
Why?
|
| Dacarbazine | 2 | 1978 | 490 | 0.010 |
Why?
|
| Leukemia | 1 | 1986 | 1673 | 0.010 |
Why?
|
| Tritium | 2 | 1974 | 206 | 0.010 |
Why?
|
| Thymidine | 2 | 1974 | 152 | 0.010 |
Why?
|
| Folic Acid Antagonists | 1 | 1976 | 46 | 0.010 |
Why?
|
| Triazenes | 1 | 1976 | 2 | 0.010 |
Why?
|
| Phenotype | 1 | 2007 | 6353 | 0.010 |
Why?
|
| Dactinomycin | 1 | 1976 | 145 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2002 | 1330 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1982 | 3069 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1980 | 748 | 0.010 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2002 | 1451 | 0.010 |
Why?
|
| Brain Diseases | 1 | 1978 | 403 | 0.010 |
Why?
|
| Puromycin | 1 | 1974 | 15 | 0.010 |
Why?
|
| Peritoneal Neoplasms | 1 | 1981 | 835 | 0.010 |
Why?
|
| Concanavalin A | 1 | 1974 | 66 | 0.010 |
Why?
|
| Cytidine | 1 | 1974 | 24 | 0.010 |
Why?
|
| Pneumonia | 1 | 1980 | 765 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1987 | 3119 | 0.010 |
Why?
|
| Phosphotransferases | 1 | 1974 | 82 | 0.010 |
Why?
|
| Granulocytes | 2 | 1987 | 232 | 0.010 |
Why?
|
| Leiomyosarcoma | 1 | 1976 | 254 | 0.010 |
Why?
|
| Staphylococcus | 1 | 1974 | 87 | 0.010 |
Why?
|
| Uridine | 1 | 1974 | 61 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 1974 | 250 | 0.010 |
Why?
|
| Telephone | 1 | 1973 | 162 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 7982 | 0.010 |
Why?
|
| Electrocardiography | 1 | 1979 | 1250 | 0.010 |
Why?
|
| Candidiasis, Cutaneous | 1 | 1971 | 4 | 0.010 |
Why?
|
| Blood Protein Disorders | 1 | 1971 | 3 | 0.010 |
Why?
|
| gamma-Globulins | 1 | 1971 | 21 | 0.010 |
Why?
|
| Lymphoma | 1 | 1980 | 1489 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1971 | 104 | 0.010 |
Why?
|
| Education, Medical, Continuing | 1 | 1973 | 252 | 0.010 |
Why?
|
| Health Education | 1 | 1973 | 315 | 0.010 |
Why?
|
| Hypertension | 1 | 1980 | 1576 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 1971 | 274 | 0.010 |
Why?
|
| Multiple Myeloma | 2 | 1980 | 2237 | 0.010 |
Why?
|
| Heavy Chain Disease | 1 | 1970 | 1 | 0.010 |
Why?
|
| Plasma Cells | 1 | 1971 | 197 | 0.010 |
Why?
|
| Injections, Intravenous | 2 | 1981 | 579 | 0.010 |
Why?
|
| Platelet Count | 2 | 1981 | 495 | 0.010 |
Why?
|
| Kinetics | 2 | 1984 | 2096 | 0.010 |
Why?
|
| Brain | 1 | 1982 | 4219 | 0.010 |
Why?
|
| Infant | 1 | 1984 | 13889 | 0.000 |
Why?
|
| Bence Jones Protein | 2 | 1980 | 10 | 0.000 |
Why?
|
| Organ Size | 1 | 1969 | 733 | 0.000 |
Why?
|
| Spleen | 1 | 1969 | 698 | 0.000 |
Why?
|
| Recombinant Proteins | 1 | 1991 | 2934 | 0.000 |
Why?
|
| Phlebitis | 1 | 1984 | 8 | 0.000 |
Why?
|
| Leukocytes | 2 | 1980 | 420 | 0.000 |
Why?
|
| Animals, Newborn | 1 | 1969 | 1348 | 0.000 |
Why?
|
| Central Nervous System Diseases | 1 | 1984 | 129 | 0.000 |
Why?
|
| Mustard Compounds | 1 | 1982 | 9 | 0.000 |
Why?
|
| Immunoelectrophoresis | 2 | 1971 | 37 | 0.000 |
Why?
|
| Myeloma Proteins | 1 | 1980 | 27 | 0.000 |
Why?
|
| Injections, Intramuscular | 1 | 1981 | 256 | 0.000 |
Why?
|
| Pseudomonas | 1 | 1980 | 22 | 0.000 |
Why?
|
| Sella Turcica | 1 | 1979 | 25 | 0.000 |
Why?
|
| Vasopressins | 1 | 1979 | 61 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1986 | 1521 | 0.000 |
Why?
|
| Digestive System | 1 | 1979 | 115 | 0.000 |
Why?
|
| Fusarium | 1 | 1979 | 55 | 0.000 |
Why?
|
| Triiodothyronine | 1 | 1978 | 76 | 0.000 |
Why?
|
| Monitoring, Physiologic | 1 | 1982 | 517 | 0.000 |
Why?
|
| Angina Pectoris | 1 | 1978 | 89 | 0.000 |
Why?
|
| Thyroxine | 1 | 1978 | 116 | 0.000 |
Why?
|
| Pruritus | 1 | 1978 | 87 | 0.000 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1978 | 121 | 0.000 |
Why?
|
| Lymphatic Diseases | 1 | 1978 | 129 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1980 | 1078 | 0.000 |
Why?
|
| Cell Survival | 1 | 1984 | 3064 | 0.000 |
Why?
|
| Pituitary Neoplasms | 1 | 1979 | 211 | 0.000 |
Why?
|
| Central Nervous System | 1 | 1979 | 450 | 0.000 |
Why?
|
| Registries | 1 | 1985 | 2300 | 0.000 |
Why?
|
| Thyroid Gland | 1 | 1978 | 360 | 0.000 |
Why?
|
| Myeloproliferative Disorders | 1 | 1984 | 868 | 0.000 |
Why?
|
| Thoracic Neoplasms | 1 | 1979 | 343 | 0.000 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1979 | 403 | 0.000 |
Why?
|
| Myocardium | 1 | 1982 | 1343 | 0.000 |
Why?
|
| Syndrome | 1 | 1978 | 1377 | 0.000 |
Why?
|
| Sex Factors | 1 | 1980 | 2198 | 0.000 |
Why?
|
| Body Weight | 1 | 1979 | 1324 | 0.000 |
Why?
|
| Dogs | 1 | 1976 | 1173 | 0.000 |
Why?
|
| District of Columbia | 1 | 1973 | 17 | 0.000 |
Why?
|
| Alabama | 1 | 1973 | 45 | 0.000 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1973 | 202 | 0.000 |
Why?
|
| Peptide Biosynthesis | 1 | 1971 | 20 | 0.000 |
Why?
|
| Candida albicans | 1 | 1971 | 182 | 0.000 |
Why?
|
| Immunodiffusion | 1 | 1970 | 44 | 0.000 |
Why?
|
| Immunochemistry | 1 | 1970 | 61 | 0.000 |
Why?
|
| Haplorhini | 1 | 1970 | 137 | 0.000 |
Why?
|
| Carbohydrates | 1 | 1970 | 68 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1970 | 634 | 0.000 |
Why?
|
| Antigens | 1 | 1970 | 297 | 0.000 |
Why?
|
| Mitosis | 1 | 1971 | 622 | 0.000 |
Why?
|
| Rabbits | 1 | 1970 | 979 | 0.000 |
Why?
|
| Referral and Consultation | 1 | 1973 | 937 | 0.000 |
Why?
|
| Epitopes | 1 | 1970 | 695 | 0.000 |
Why?
|
| Communication | 1 | 1973 | 912 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1971 | 4281 | 0.000 |
Why?
|
| Peptides | 1 | 1970 | 1504 | 0.000 |
Why?
|
| Asthma | 1 | 1971 | 909 | 0.000 |
Why?
|